The Anti-SARS-CoV-2 IgG Antibody Response of Participants Vaccinated with Different Vaccine Combination
The Anti-SARS-CoV-2 IgG Antibody Response of Participants Vaccinated with Different Vaccine Combination
Introduction: In current literature, there are lots of description about the new Coronavirus, named as SARS-CoV-2 by World Health Organization (WHO). Basically, SARS-CoV-2 has been identified as the etiological agent of COVID-19 disease which was reported a group of patients with pneumonia of unknown cause in Wuhan, China, in December 2019. In this work, our aim was to investigate the anti-S1 IgG response that occurs after different kinds and different doses of SARS-CoV-2 vaccines and the demographic characteristics of participants.
Materials and Methods: A total of 299 participants were included in this study to detect the Anti-SARS-CoV-2 IgG antibody. The only inclusion criteria for this study were being vaccinated minimum 2-doses of any SARS-CoV-2 vaccine. For detecting the antibody levels of participants, Anti-SARS-CoV-2 ELISA (IgG) test kit which applies a recombinant S1 subunit of the SARS-CoV-2 spike protein, enabling detection of IgG antibodies was used.
Results: Out of 299 individuals, 128 (42.8%) were male and 171 (57.2%) were female in our study. The mean age of individuals 35.11±8.13 (minimum: 19 and maximum: 59). The lowest antibody levels were belong to Group 2 and Group 3 (138.66±25.41, and 82.09±63.42 IU/ml, respectively), while the highest antibody levels were belong to Group 6 (239.35±18.73 IU/ml).
Discussion: According to our result, a significantly higher humoral immunogenicity of the SARS-CoV-2 BioNTech compared with the CoronaVac vaccine. A significant increase in serological response was achieved with the 3rd or 4th dose of vaccine; however, it had better to be vaccinated with BioNTech after 2nd dose of COVID-19 vaccine.
Keywords:
SARS-CoV-2, COVID-19, Antibody response CoronaVac, BioNTech,
___
- 1. Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol. 2022;94(1):173-7.
- 2. Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases - Wuhan, China 2019-2020. China CDC Wkly. 2020;2(4):61-2.
- 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
- 4. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjw2cWgBhDYARIsALggUho-1UZZ8-nq5RpD1yJSJATo6ywV8GchTA7dME79slHbQsjc7mOEVPgaAodvEALw_wcB 2023 [
- 5. Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682-7.
- 6. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1):e0034121.
- 7. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643-50.
- 8. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-12.
- 9. Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune Response to SARS-CoV-2 Vaccines. Biomedicines. 2022;10(7).
- 10. Bayram A, Demirbakan H, Gunel Karadeniz P, Erdogan M, Kocer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560-7.
- 11. Barin B, Kasap U, Selcuk F, Volkan E, Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022;3(4):e274-e83.
- 12. Sağlık İ, Payaslıoğu M, Aydın Başkılıç R, Ener B, Ağca H, Tüzemen N, et al. Antibody Response (IgM and IgG) After Two Doses of Immunization Against SARS-CoV-2 and Comparison of Two Different Third Dose Administrations. Journal of Molecular Virology and Immunology. 2023;4(1):1-14.
- 13. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39-41.
- 14. Yavuz E, Gunal O, Basbulut E, Sen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol. 2022;94(8):3768-75.
- 15. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2022;27(4):301-10.
- 16. Clavero R, Parra-Lucares A, Mendez-Valdes G, Villa E, Bravo K, Mondaca E, et al. Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. Vaccines (Basel). 2022;10(9).
- 17. Saure D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56-63.
- 18. Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med. 2022;20(1):216.
- 19. Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, et al. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. J Clin Virol. 2022;156:105273.
- Başlangıç: 2022
- Yayıncı: Erzurum Teknik Üniversitesi
Sayıdaki Diğer Makaleler
The Apoptotic Effects of a Proteasome Inhibitor on Caco-2 Colon Carcinoma Cells
Salicylic acid improves somatic embryogenesis system in triticale using mature embryos
İsmail BEZİRGANOGLU, Büşra YAZICILAR
Ebubekir DİRİCAN, Yasemin KAYA
Murat KARAMEŞE, Abdullah GÜMÜŞ
Genetic diversity of Galeodes populations (Arachnida: Solifugae) on Bolkar Mountains
Hydrophobins: the Amphiphilic Proteins Produced in Filamentous Fungi